Early oral anticoagulation is non-inferior to delayed treatment in patients with ischemic stroke and atrial fibrillation
1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or ...
Tag: apixaban
#VisualAbstract: Apixaban does not significantly prevent recurrent stroke after cryptogenic stroke in patients with atrial cardiopathy
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Apixaban lowers the risk of stroke in subclinical atrial fibrillation
1. In this randomized controlled trial, apixaban lowered the risk of stroke or systemic embolism significantly more than aspirin in ...
#VisualAbstract: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Apixaban is associated with a lower risk of gastrointestinal bleeding than other direct oral anticoagulants
1. In this population-based cohort study, apixaban was associated with a lower risk of gastrointestinal bleeding (GIB) as compared to ...
Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease
1. In comparison to rivaroxaban, apixaban was associated with a lower rate of bleeding events and embolic events amongst adults ...
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
Click to read this study in JAMA Network Open.
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
ANNEXA-A and ANNEXA-R trials: Andaxanet Alfa for Reversal of Apixaban and Rivaroxaban [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation
1. Asundexian 50 mg resulted in a lower rate of bleeding compared to apixaban 5 mg twice daily. 2. The ...
Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation
1. In patients with atrial fibrillation over 65, treatment with rivaroxaban compared to apixaban was associated with a significantly increased ...